Brief: Relay Therapeutics Announces Positive Interim Data For Rly-2608

Relay Therapeutics

09/09/2024 11:55

Sept 9 (Reuters) - RELAY THERAPEUTICS  RLAY.O :
    * RELAY THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR
RLY-2608
DEMONSTRATING CLINICALLY MEANINGFUL PROGRESSION FREE SURVIVAL
    * RELAY: 33% ORR ACROSS ALL PATIENTS & 53% ORR IN PATIENTS
WITH
KINASE MUTATIONS AT RECOMMENDED PHASE 2 DOSE
    * RELAY: 9.2-MONTH MEDIAN PFS IN HEAVILY PRE-TREATED
PATIENTS WITH
PI3KΑ-MUTATED, HR+/HER2- METASTATIC BREASTCANCER AT RECOMMENDED
PHASE 2 DOSE
    * RELAY: AT RP2D, 2 PATIENTS DISCONTINUED TREATMENT DUE TO
ADVERSE
EVENTS, 1 PATIENT EXPERIENCED GRADE 3 HYPERGLYCEMIA
    * RELAY: DATA SUPPORT PLANNED INITIATION OF 2L PIVOTAL TRIAL
IN
2025
    * RELAY: TRIPLET COMBINATION WITH RIBOCICLIB EXPECTED TO
MOVE INTO
DOSE EXPANSION IN H1 2025
    * RELAY: TRIPLET COMBINATION WITH ATIRMOCICLIB (CDK4)
REMAINS ON
TRACK TO START BEFORE YEAR-END
    * RELAY: FOR LIRAFUGRATINIB, FDA SUGGESTED CO FILE NDA IN
CHOLANGIOCARCINOMA, FOLLOWED BY SNDA FOR FGFR2 FUSIONS
    * RELAY: PLANS TO SEEK GLOBAL COMMERCIALIZATION PARTNER FOR
LIRAFUGRATINIB

Source text for Eikon:  ID: 
Further company coverage:  RLAY.O 

 ((Reuters.Briefs@thomsonreuters.com;))